Larimar Therapeutics Inc (LRMR) Transcripts
Larimar Therapeutics Inc To Provide a Program Update Transcript
Feb 12, 2024
Larimar Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 07, 2023
Larimar Therapeutics Inc To Discuss Phase 2 dose exploration trial of CTI-1601 Transcript
Jul 25, 2023
Larimar Therapeutics Inc CTI-1601 May 2023 Program Update Conference Call Transcript
May 15, 2023
Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 04, 2023
9Larimar Therapeutics Inc at Guggenheim Healthcare Talks: Immunology and Neurology Day Transcript
Nov 15, 2022
Larimar Therapeutics Inc To Discuss Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Transcript
Sep 14, 2022
Larimar Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Q1 2021 Larimar Therapeutics Inc Earnings Call Transcript
May 11, 2021
$8.36
(-36.28%)
Earnings
Zafgen Inc and Chondrial Therapeutics Announce Definitive Merger Agreement - M&A Call Transcript
Dec 18, 2019
Q4 2018 Zafgen Inc Earnings Call Transcript
Mar 11, 2019
Earnings